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cTATE-OF-THE-ART PAPER415Understanding the Limitations of Published Clinical Trialsanjay Kaul, George A. Diamond
aul and Diamond review the strengths and limitations of randomized controlled trials to
uide clinical decision making. The difference between statistical significance and clinical
ignificance is reviewed. The potential to obscure with composite end points is highlighted.
inally, many trials publish subgroup analyses without the use of statistically appropriate
djustment for interactions and multiple comparisons. These potential faults are discussed in
his review and are highlighted with examples from recent clinical trials. The accompanying
gures will help the clinician to visualize these mathematical concepts.OMMENTARY428Randomized Trials, Statistics, and Clinical Inferenceregg W. Stone, Stuart J. Pocock
n a commentary accompanying the state-of-the-art paper, Stone and Pocock agree with
any of the recommendations for interpreting the results of randomized clinical trials
RCTs), although they take issue with the specific examples given. The authors lament that
CTs are not infrequently poorly designed, implemented with inadequate quality control,
nd/or subject to inappropriate interpretation or generalization. Many common and egregious
isrepresentations from RCTs are due to the fallacies that arise from underpowered studies,
articularly in regard to composite outcomes, secondary end points, and subgroup analyses.
he authors conclude with the hope that the paper by Kaul and Diamond and this
ommentary will spur improved design of future RCTs and thoughtful, critical appraisal by
aregivers, editors, and regulatory bodies.(continued on page A-25)
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pLINICAL TRIALS432Randomized Trial of CABG Versus PCI in Diabetic Patientskhil Kapur, Roger J. Hall, Iqbal S. Malik, Ayesha C. Qureshi, Jeremy Butts, Mark de Belder,
ndreas Baumbach, Gianni Angelini, Adam de Belder, Keith G. Oldroyd, Marcus Flather,
ichael Roughton, Petros Nihoyannopoulos, Jens Peder Bagger, Kenneth Morgan, Kevin J. Beatt
he CARDia (Coronary Artery Revascularization in Diabetes) trial investigated the safety
nd efficacy of percutaneous coronary intervention (PCI) with stents compared with coronary
rtery bypass grafting (CABG) in patients with diabetes and multivessel disease. The primary
utcome was a composite of death, myocardial infarction (MI), or stroke, and over 500
iabetic patients were randomized to PCI or CABG with a noninferiority design. At 1 year,
he composite rate of death, MI, and stroke was 10.5% in the CABG group versus 13.0% in
he PCI group (p  0.39). All-cause mortality was the same at 3.2%, and the secondary
omposite of major adverse coronary and cerebral events, including repeat revascularization,
avored CABG at 11% versus 19%. The 1-year results of the CARDia trial do not
emonstrate that PCI is noninferior to CABG for the combined end point of death, MI, and
troke, although longer follow-up is pending.EART FAILURE441NT-proBNP Can Identify Asymptomatic Subjects at Risk of Developing HFhristopher R. deFilippi, Robert H. Christenson, John S. Gottdiener, Willem J. Kop, Stephen L. Seliger
eFilippi and colleagues sought to determine if measurement of N-terminal pro–B-type
atriuretic peptide (NT-proBNP) would provide prognostic information in elderly patients
ith no history of heart failure (HF). NT-proBNP was measured at baseline and 2 to 3 years
ater in nearly 3,000 older adults. Those with NT-proBNP levels in the highest quintile
268 pg/ml) were 3 times more likely to develop HF or to die from a cardiovascular (CV)
ause than those in the lowest quintile (47 pg/ml). Serial testing revealed that subjects with
nitially low NT-proBNP who developed a 25% increase to 190 pg/ml were 2 times more
ikely to develop HF or suffer a CV death compared with those with sustained low levels.
hese results suggest that NT-proBNP levels independently predict heart failure and CV
eath in older adults, and serial examinations provide further prognostic information.
ditorial Comment: Matthew G. Daly, Christopher M. Frampton, Richard W. Troughton,
. 451(continued on page A-26)
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454emodialysis Linked to Impaired Vascular
Function Through Release of Free Hemoglobinhristian Meyer, Christian Heiss, Christine Drexhage, Eva S. Kehmeier, Jan Balzer, Anja Mühlfeld,
arc W. Merx, Thomas Lauer, Harald Kühl, Jürgen Floege, Malte Kelm, Tienush Rassaf
eyer and colleagues investigated the mechanisms that underlie endothelial dysfunc-
ion in patients undergoing hemodialysis. Hemodialysis significantly impaired endo-
helial function measured with flow-mediated dilation (FMD) of the brachial artery.
his was accompanied by an increase in cell-free plasma hemoglobin; the hemoglo-
in absorbs free nitric oxide (NO) such that its bioavailability was reduced by more
han 70%. Oxidation of the released hemoglobin prevented the consumption of NO,
nd there was an inverse correlation between free hemoglobin and the change in
MD. These results link hemodialysis to impaired vascular function and suggest that
nterventions that reduce red blood cell hemolysis or oxidize the plasma hemoglobin
ay reduce the risk of cardiovascular events in patients undergoing hemodialysis.ditorial Comment: Chenell L. Donadee, Mark T. Gladwin, p. 460ARDIOMYOPATHY
463utoantibodies Against G-Protein–Coupled Receptors
May Lead to Chagas’ Cardiomyopathy and Megacolonerd Wallukat, Silvia Gilka Muñoz Saravia, Annekathrin Haberland, Sabine Bartel, Raul Araujo,
regorio Valda, Diana Duchen, Ivan Diaz Ramirez, Adrian Constantin Borges, Ingolf Schimke
hagas’ disease affects 15 million people, mostly in Latin America. Despite being lifelong
arasite carriers, two-thirds of the patients remain clinically asymptomatic while one-third
ventually develop either a cardiomyopathy or megacolon. Wallukat and colleagues studied
he expression of autoantibodies (AAB) against G-protein–coupled receptors in patients who
eveloped Chagas’ cardiomyopathy and/or megacolon and also in asymptomatic subjects with
hagas’ disease. Nearly all Chagas’ patients with symptoms had high levels of AAB with
pecific patterns seen in those with either cardiomyopathy and/or megacolon. Similar patterns
ere seen in some asymptomatic subjects with a frequency that mirrors epidemiological data
n the likelihood of chronic carriers developing symptoms. Measurement of AAB might be a
seful tool for risk assessment in asymptomatic subjects with Chagas’ disease.(continued on page A-32)
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pRE-CLINICAL RESEARCH469CTGF and Rac1 May Predispose to Developing AFAng II
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CTGFliver Adam, Daniel Lavall, Katharina Theobald, Mathias Hohl, Markus Grube, Sabine Ameling,
ark A. Sussman, Stephan Rosenkranz, Heyo K. Kroemer, Hans-Joachim Schäfers, Michael Böhm,
lrich Laufs
dam and colleagues used a series of experiments to study atrial structural remodel-
ng that contributes to the pathogenesis of atrial fibrillation (AF). The studies began
y performing transcriptional profiling of left atrial (LA) myocardium from patients
ith AF and sinus rhythm (SR), which showed a marked up-regulation of connective
issue growth factor (CTGF) expression in those with AF. This was associated with
ncreased fibrosis, nicotinamide adenine dinucleotide phosphate-oxidase, Rac1, and
hoA activity, and increased angiotensin II levels. In vitro studies of rat cardiac
yocytes and fibroblasts showed that inhibitors of Rac1, including simvastatin, pre-
ented the up-regulation of CTGF. Finally, in mice predisposed to developing AF,
nhibition of Rac1 by oral statin treatment prevented up-regulation of these pathways
nd reduced the incidence of AF. These data identify CTGF as an important media-
or of atrial structural remodeling that predisposes to developing AF.ditorial Comment: James K. Liao, p. 481YEAR IN CARDIOLOGY SERIES EAR IN CARDIOLOGY SERIES483Year in Cardiac Imagingaymond J. Gibbons, Philip A. Araoz, Eric E. Williamson
his review by Gibbons and colleagues highlights the most important literature regarding
ingle-photon emission computed tomography (CT) myocardial perfusion imaging, cardiac
ositron emission tomography, cardiac CT, and cardiac magnetic resonance imaging from
pproximately July 2008 to June 2009. Almost 100 papers are highlighted with summaries of
he key findings and commentary to place them in context with other literature. The authors
ope that this review will encourage the reader to examine some of these papers in more
etail and, ultimately, to more carefully apply the correct imaging modality to each clinical
roblem.
